Annovis Bio, Inc. (ANVS) Form 8-K — Nov 5, 2026
Annovis Bio entered into an underwriting agreement with Canaccord Genuity on November 5, 2026, for a public offering of 19,000,000 shares plus 2,000,000 pre-funded warrants, each unit sold with an accompanying warrant for one additional share at $1.00, for expected gross proceeds of approximately $21.0 million. Accompanying warrants total 21,000,000 shares with a $1.00 exercise price and five-year term, creating a significant additional share overhang if exercised. One company director is purchasing 5,000,000 units for $5.0 million at the same price as other investors.
Key figures
- Gross Proceeds
- 21000000
- Offering Price
- 1
- Shares Offered
- 19000000
- Pre funded warrants
- 2,000,000 pre-funded warrants at $0.9999 (exercise price $0.0001)
- Accompanying warrants
- 21,000,000 warrants at $1.00 exercise price, 5-year term
- Director participation
- 5,000,000 units for $5,000,000
- Beneficial ownership limit
- 4.99% (electable to 9.99%, increasable to 19.99% after 61 days notice)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.